Wall Street faces a major test this week as fresh inflation data and big bank earnings put the economy back in focus. Meanwhile, AI spending continues to fuel acquisitions and chip demand, while healthcare and capital markets remain active with new approvals, financing deals, and upcoming IPOs.
Most Investors Miss (Sponsored)
Wealthy investors have used it for years.
Most Main Street investors have never heard of it.
You can get started with as little as $100 with Wall Street’s best-kept secret.
Discover What It Is →
*Past performance does not guarantee future results. Warrants are speculative and you may lose your entire investment. Only invest money you can afford to lose.
Futures at a Glance📈
Futures are edging higher as Wall Street gears up for a busy week of bank earnings and inflation data. Renewed Middle East tensions are keeping oil prices volatile, while elevated Treasury yields and concerns over stretched AI valuations are tempering enthusiasm ahead of Wednesday’s CPI report.
Want to make sure you never miss a pre-market alert?
Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.
Email’s great. Texts are faster.
You’ll be first in line when the market starts moving.
What to Watch
Earnings (Time Not Supplied / Estimated):
· Nurix Therapeutics, Inc. [NRIX]
· PT Perusahaan Gas Negara Tbk [PPAAF]
· AMTD Digital Inc. [HKD]
· CytoDyn Inc. [CYDY]
· GoldMining Inc. [GLDG]
Economic Reports:
· Cleveland Fed President Beth Hammack speech: 12:50 pm
Market Pulse
Wall Street faces a pivotal inflation test Wednesday as September CPI figures land midweek, with oil-driven price pressures threatening to revive rate-hike bets ahead of the Fed's October meeting.
Major U.S. banks open earnings season Tuesday as JPMorgan, Citigroup and Goldman Sachs report, offering an early read on consumer credit, trading revenue, and higher borrowing costs.
AI & Semiconductors
Amazon is reportedly negotiating a $7 billion acquisition of AI startup Decart as its models simulate real-world environments for robotics, autonomous-driving development, and real-time video applications.
TSMC could deliver its sixth consecutive record quarterly profit as AI chip orders lift demand, with analysts expecting a 65% annual earnings increase when results arrive Thursday.
Healthcare & Biotech
Teva won FDA approval for Weltruza, a monthly schizophrenia injection after regulators cleared the new treatment, expanding its long-acting medicines partnership with France's Medincell for adult patients.
Vertex reported encouraging cystic fibrosis data in young children after ALYFTREK improved pancreatic function in some, allowing some young patients to discontinue ongoing enzyme replacement therapy.
Tax Savings Options (Sponsored)
Capital gains taxes can take a bigger bite out of your profits than expected.
Fortunately, some deductions may help reduce the impact — including:
Investment-related expenses
Certain real estate selling costs
Because rules and eligibility vary, many investors turn to fiduciary financial advisors for guidance.
Find an Advisor Match.
Finance & Deals
Italy's INWIT could become another private equity buyout target as major shareholders explore takeover financing amid escalating contract disputes with its biggest Italian telecom customers.
Tencent is preparing another international bond sale with dollar and offshore yuan notes that could carry maturities as long as 30 years following June's $4.66 billion issue.
Capital & IPOs
India's Zetwerk is seeking a $2.6 billion IPO valuation as its $518 million offering opens Thursday, testing demand for contract manufacturing businesses in an active listing market.
Moonshot's planned Hong Kong IPO faces a governance complication as executives negotiate a shareholder settlement over alleged wrongdoing that the Chinese AI startup's leadership denies.
'Dark pools' -- private venues where large block trades happen away from public exchanges -- grew substantially in use after which 2005 SEC rule change?
Movers and Shakers
First Tracks Biotherapeutics [TRAX]: Premarket Move: +14%
First Tracks Biotherapeutics surged after announcing upcoming Phase 1b results for its experimental celiac disease treatment, ANB033. The 30-patient study evaluates whether the drug can prevent intestinal damage caused by gluten exposure, with results scheduled for Monday morning. The announcement puts a major clinical catalyst directly in focus, fueling speculative buying ahead of the data release.
IREN [IREN]: Premarket Move: +6%
IREN rebounded after last week's sharp selloff triggered by allegations of reliability problems at its AI data centers. Research firm SemiAnalysis reported customer complaints involving power outages, network disruptions, and storage failures at older Canadian facilities, sending shares down more than 13% across two sessions. Monday's recovery suggests some traders are buying the dip, although questions about infrastructure reliability remain unresolved.
Albemarle [ALB]: Premarket Move: −3%
Albemarle slipped as recent analyst price-target cuts reinforced concerns about the lithium market's uneven recovery. Argus Research recently slashed its target from $230 to $135, although it maintained a Buy rating, citing lithium prices that remain well below historical peaks. The pullback reflects continued uncertainty around lithium supply and pricing, even as analysts anticipate improving market conditions heading into 2027.
Elite Picks (Sponsored)
This report focuses on a narrow group of stocks identified through a detailed screening process.
Analysts apply a combination of metrics to narrow down potential opportunities.
Past selections have shown strong momentum, but no outcomes are guaranteed.
The newest edition is now open for access.
Get the report now.
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
Everything Else
🔬 The Magnificent Seven matured and seven new contenders are already emerging quietly with the fundamentals and growing influence analysts watch before a new leadership wave takes hold.
⚡ Alphabet's Google signed a massive power deal with Constellation Energy, including $4.3 billion in nuclear upgrades to support growing data-center demand.
🏥 GE HealthCare agreed to acquire Sofie Biosciences for $945 million, expanding into radioactive imaging agents used to detect cancer and other diseases.
🏗️ CRH expanded its European infrastructure footprint with an agreement to acquire NCC's aggregates and asphalt operations in Denmark and Finland.
💾 Cirrus Logic acquired Italian chipmaker INVENTVM, adding power-management technology and engineering capabilities to support expansion into new markets.
💰 Tencent announced a new bond offering, returning to international debt markets after raising $4.66 billion in June.
You Read This Far. Here's Where the Real Work Lives.
We run three live portfolios on Autopilot, and everything about them is public: every position, every allocation, every trade, visible the moment it happens.
We keep our own money in each one, because analysis you won't fund yourself is just content.
THE UNBREAKABLE STACK
Our growth book: durable software and cybersecurity names built to compound quietly for years.
THE HORMUZ PREMIUM
Our energy thesis: built for how that sector actually pays, over quarters, not headlines.
THE ELON INDEX
Our conviction bet on the Musk universe: Tesla, and the companies orbiting his ventures, energy, AI, infrastructure. High-beta by design, for investors who want direct exposure to the trade rather than watching it from the sidelines.
And here's the part that makes it effortless: Autopilot does the trading for you. Connect the brokerage you already use (Robinhood, Schwab, Fidelity, and more) and every move we make gets mirrored in your own account automatically.
Your money never leaves your brokerage. It stays in your account, under your control, and you can override any trade or disconnect anytime. Autopilot even rebalances automatically when allocations drift, and you get a notification every time something happens.
No watching tickers. No timing entries. No fat-finger mistakes at market open. You pick the portfolio, we do the work, your account follows along.
Pick the one that fits your risk level, or run all three:
Live portfolios, real positions, our own capital at stake. Your funds stay in your own brokerage account. Past performance doesn't guarantee future results.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
